eFFECTOR Therapeutics Inc · OTC:EFTR
eFFECTOR Therapeutics — SPAC Merger (May 2021)
37 slides from eFFECTOR Therapeutics's SPAC merger presentation, May 27, 2021
Slide 1: Next Generation Targeted Therapy for Cancer
Next Generation Targeted Therapy for Cancer Investor Presentation May 27, 2021 ..
Slide 2: Disclaimer
DISCLAIMER ABOUT THIS PRESENTATION This presentation is for informational purpose sonly to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Locust Walk Acquisition Corp. (LWAC) and eFFECTOR Therapeutics, Inc.
Slide 3: eFFECTOR Meets Demanding Criteria of Locust Walk Acquisition Corp
eFFECTOR MEETS DEMANDING CRITERIA OF LOCUST WALK ACQUISITION CORP • Locust Walk Acquisition Corp (LWAC) is a $175M SPAC focused on biotechnology with a comprehensive investment thesis that has been used to evaluate over 90 potential targets PRELIMINARY CRITERIA Strong Investor Base Platform Technolo
Slide 4: Transaction Overview
TRANSACTION OVERVIEW eFFECTOR has entered into a definitive agreement to merge with Locust Walk Acquisition Corp (“LWAC”) • Implied post-money enterprise value of ~$420 million • Transaction to be funded through a combination of $60 million committed PIPE financing plus up to $175 million from LWAC’
Slide 5: Transaction Overview
TRANSACTION OVERVIEW Illustrative Post-Money Valuation at Close Illustrative Estimated Transaction Cash Sources and Uses PF Transaction ($ mm) Cash Sources ($ mm) eFFECTOR Illustrative Share Price $10.00 SPAC Cash in Trust $175 PF Shares Outstanding 62.6 PIPE 60 Total Equity Value $626 Total Cash So
Slide 6: Major Unmet Need in Oncology: Therapeutic Strategies Designed to Outsmart Cancer
MAJOR UNMET NEED IN ONCOLOGY: THERAPEUTIC STRATEGIES DESIGNED TO OUTSMART CANCER Cancer is a complex, aggressive disease driven by multiple factors that enable it to evolve to evade existing therapies. • Immuno-oncology and targeted therapies have improved outcomes, but only work for subsets of pati
Slide 7: Imagine Cancer Medicines That Are Designed To
IMAGINE CANCER MEDICINES THAT ARE DESIGNED TO: • Be well tolerated and easier to take • Shut down multiple drivers of cancer simultaneously • Reactivate the immune system to eliminate tumors • Make existing treatments work better and longer • Delay need for toxic chemotherapy 6 ..
Slide 8: The Next Phase in Cancer Therapeutics
THE NEXT PHASE IN CANCER THERAPEUTICS • Pioneering Selective Translation Regulator Inhibitors (STRIs) designed to: NOVEL • Simultaneously block production of multiple disease-driving proteins with a single drug PLATFORM • Knock down oncoproteins, immune suppression and resistance to create better ou
Slide 9: Experienced Leadership Team
EXPERIENCED LEADERSHIP TEAM Steve Worland, Ph.D. Founder, President, CEO and Director Premal Patel, M.D., Ph.D. CMO Alana McNulty CBO Mike Byrnes CFO Mark Densel VP, Development Operations Scientific Advisors Institution Expertise Kevan Shokat, PhD UCSF, eFFECTOR Co-founder Translation & KRAS Davide
Slide 10: STRI Platform: Targeting Key Node in Cancer
STRI PLATFORM: TARGETING KEY NODE IN CANCER • Novel targets located at key node where two important cancer pathways converge and drive production of multiple disease- driving proteins • Multiple potential advantages of inhibiting targets related to the eIF4F complex ü Simultaneously decrease product
Slide 11: Robust Pipeline: Multiple STRIs in Development
ROBUST PIPELINE: MULTIPLE STRIs IN DEVELOPMENT Program Global Anticipated Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 (Target) Rights Milestones H1 2022: NSCLC – 1L Extension in combo with pembro Topline data readout Tomivosertib H2 2022: Topline (MNK 1/2i) NSCLC – 1L in combo with pembr
Slide 12: Tomivosertib
Tomivosertib MNK 1/2 Inhibitor Designed to stimulate activation, prevent exhaustion and prolong memory of T cells ..
Slide 13: Tomivosertib: Potential to Delay and Reverse Resistance to CPI Therapy
TOMIVOSERTIB (TOMI): POTENTIAL TO DELAY AND REVERSE RESISTANCE TO CPI THERAPY • Checkpoint inhibitors (CPIs) have advanced oncology treatment but: Most patients don’t respond – The majority of responders develop resistance and must progress to more toxic chemotherapeutics agents • In combination wit
Slide 14: Tomivosertib Designed to Reprogram T Cells to Enhance Anti-Tumor Activity
TOMIVOSERTIB DESIGNED TO REPROGRAM T CELLS TO ENHANCE ANTI-TUMOR ACTIVITY T Cells Tomivosertib (Tomi) designed to delay T cell exhaustion and reinvigorate anti-tumor activity to achieve: • Increased target cell killing • Simultaneous downregulation of several key checkpoint proteins associated with
Slide 15: Tomivosertib Designed to Downregulate Multiple Immunosuppressive Proteins in One Pill
TOMIVOSERTIB DESIGNED TO DOWNREGULATE MULTIPLE IMMUNOSUPPRESSIVE PROTEINS IN ONE PILL • Designed to reprogram T cells from within and in preclinical studies inhibited production of multiple immunosuppressive proteins that are the targets of individual IO drugs • PD-1 and PD-L1 ($25B+ worldwide sales
Slide 16: Tomivosertib: Generally Well Tolerated with Single-Agent Activity
TOMIVOSERTIB: GENERALLY WELL TOLERATED WITH SINGLE-AGENT ACTIVITY* • Tomivosertib was generally well tolerated at the recommended Phase 2 dose (RP2D) as single agent and in combination with anti-PD-(L)1 agents – Safety profile when combined with anti-PD-(L)1 agents comparable to anti-PD-(L)1 alone •
Slide 17: Phase 2a: Prolonged PFS When Combined with Anti-PD-(L)1 Agents
PHASE 2A: PROLONGED PFS WHEN COMBINED WITH ANTI-PD-(L)1 AGENTS • 39 patient Phase 2a study showed encouraging activity in multiple tumor types* – Tomivosertib added on to patients not responding to anti-PD-(L)1 therapy with no change or break in anti-PD-(L)1 regimen • Subset including all 17 NSCLC p
Slide 18: Phase 2a: Extended PFS in NSCLC Patients Enriched in PD-L1+ Patients
PHASE 2A: DEMONSTRATED EXTENDED PFS IN NSCLC PATIENTS PARTICULARLY ENRICHED IN PD-L1+ PATIENTS All patients: mPFS of 20 weeks compared to ~7 weeks in comparative data set in similar patients in the OAK study* PD-L1+ patients: mPFS of 53 weeks (in the OAK TBP cohort, PD-L1+ status did not improve ben
Slide 19: Phase 2a: Immediate Tumor Regressions Upon Addition of Tomivosertib
PHASE 2A: IMMEDIATE TUMOR REGRESSIONS IN MULTIPLE PATIENTS UPON ADDITION OF TOMIVOSERTIB Patient on Tomi/Pembro Combo Experienced Confirmed Complete Response after ~2 Years on Combo Therapy Patient was PD-L1>50% 18 ..
Slide 20: KICKSTART: Randomized Phase 2b Trial Open for Enrollment in Two NSCLC Indications
KICKSTART: RANDOMIZED PHASE 2B TRIAL OPEN FOR ENROLLMENT IN TWO IMPORTANT NSCLC INDICATIONS – ENRICHED FOR PD-L1+ Tomivosertib + pembrolizumab KEY ELIGIBILITY 1L extension R CRITERIA: (PD on pembro) 1:1 N=60 Placebo + pembrolizumab Stage IV NSCLC No prior chemo Tomivosertib + pembrolizumab 1L R PD-L
Slide 21: Potential Market Settings – NSCLC PD-L1 > 50%
POTENTIAL MARKET SETTINGS – NSCLC PD-L1 > 50%* • Frontline represents potential $4B+ US market opportunity • Frontline extension is novel setting that delays chemotherapy potentially improving patient quality of life (~$700M+ US market opportunity) Metastatic NSCLC ≥ 50% PD-L1 w/ No Actionable Mutat
Slide 22: Zotatifin
Zotatifin eIF4A Helicase Inhibitor Oncology: Designed to downregulate key oncoproteins and cell cycle proteins ..
Slide 23: Zotatifin Designed to Inhibit Production of Key Proteins Driven by Upstream Oncogenes
ZOTATIFIN DESIGNED TO INHIBIT PRODUCTION OF KEY PROTEINS DRIVEN BY UPSTREAM ONCOGENES • Cancer signaling drives production of multiple tumor promoting proteins • Zotatifin designed to block this multi-protein upregulation in a single product • In preclinical studies, zotatifin was observed to downre
Slide 24: Preclinical Regulation of Translation by Zotatifin Was Selective for Tumor Growth Proteins
PRECLINICAL REGULATION OF TRANSLATION BY ZOTATIFIN WAS SELECTIVE FOR PROTEINS THAT DRIVE TUMOR GROWTH AND RESISTANCE At physiological concentrations in vitro, zotatifin only affected translation of ~5% of mRNAs NON-CODING SEQUENCE CODING SEQUENCE RTK proteins KRASmut protein all forms Experimental s
Slide 25: Zotatifin Demonstrated Single Agent and Combo Activity in Preclinical Studies
ZOTATIFIN DEMONSTRATED SINGLE AGENT AND COMBO ACTIVITY IN PRECLINICAL STUDIES ER+ Breast Cancer Model* KRAS G12C NSCLC Model • Zotatifin demonstrated comparable single • Zotatifin demonstrated comparable single agent activity to marketed inhibitor of agent activity to Amgen’s KRAS G12 C CDK4/6 (palb
Slide 26: Additional Program Opportunities
ADDITIONAL PROGRAM OPPORTUNITIES • Tomivosertib – Expansion into NSCLC with PD-L1 status 1-49% where CPI+chemo is standard of care as triplet (tomi+CPI+chemo) – Other immuno-responsive tumors (renal, bladder, MSI) • Zotatifin - COVID – $5M DARPA grant funding P1b trial as antiviral – Potent antivira
Slide 27: Upcoming Milestones
Upcoming Milestones ..
Slide 28: Multiple Upcoming Clinical Milestones
MULTIPLE UPCOMING CLINICAL MILESTONES 2021 2022 2023 Anticipated Milestones 2H 1H 2H 1H 2H Top line data from P2b NSCLC frontline extension Top line data from P2b NSCLC frontline Tomivosertib Expand into additional P2b indications Top line data from additional P2b indications Initiate P3 in NSCLC In
Slide 29: Outlook
OUTLOOK • Leverage strong scientific foundation as leaders in development of selective translation regulator inhibitors as a new class of therapies for cancer • Trials underway for two product candidates – Tomivosertib prolonged disease stabilization in Phase 2a study and biomarker-driven Phase 2b s
Slide 30: Risk Factors
RISK FACTORS Risks Related to Our Limited Operating History, Financial Position and Capital Requirements • We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any
Slide 31: Risk Factors (Cont'd)
RISK FACTORS (CONT’D) Risks Related to Our Reliance on Third Parties • We rely on third parties to conduct our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadl
Slide 32: Risk Factors (Cont'd)
RISK FACTORS (CONT’D) Risks Related to Our Business Operations and Industry • Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. • We are dep
Slide 33: Risk Factors (Cont'd)
RISK FACTORS (CONT’D) Risks Related to Our Intellectual Property • If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or id
Slide 34: Risk Factors (Cont'd)
RISK FACTORS (CONT’D) Risks Related to Becoming a Public Company • We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. • We will be an emerging growth company and a small
Slide 35: Risk Factors (Cont'd)
RISK FACTORS (CONT’D) Risks Related to the Business Combination • Each of LWAC and eFFECTOR will incur significant transaction costs in connection with the Business Combination. • The consummation of the Business Combination is subject to a number of conditions and if those conditions are not satisf
Slide 36: Risk Factors (Cont'd)
RISK FACTORS (CONT’D) General Risk Factors • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and int
Slide 37: Next Generation Targeted Therapy for Cancer
Next Generation Targeted Therapy for Cancer Investor Presentation May 27, 2021 ..